China’s NMPA vows to cultivate 3-5 globally competitive biopharma clusters, boost foreign investment
On September 20, China’s National Medical Products Administration (NMPA) announced policies to scale up and modernize the pharmaceutical industry, encouraging foreign-invested enterprises to produce originator drugs and high-end medical equipment domestically. The NMPA aims to cultivate three to five internationally competitive biopharmaceutical innovation clusters in key regions including Beijing-Tianjin-Hebei, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Economic Circle, while supporting Chinese firms’ overseas expansion.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
China's NMPA to Cultivate 3-5 Internationally Competitive Biopharma Clusters
On September 20, Yang Sheng, Deputy Director of China's National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that the agency will focus on cultivating 3 to 5 biopharmaceutical industry clusters with international competitiveness. The NMPA will support scaled, intensive, and high-end development of the pharmaceutical industry, encouraging the construction of smart and green factories. It will continue to support innovative development in key regions including Beijing-Tianjin-Hebei, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Twin-City Economic Circle. The NMPA also plans to support expanded opening-up and cooperation, encouraging foreign-invested enterprises to introduce originator drugs and high-end medical equipment for domestic production, while promoting Chinese enterprises to 'go global' so that Chinese drugs and medical devices can benefit people worldwide.
Read sourceChina's NMPA Vows to Boost Pharma Industry, Cultivate Biopharma Innovation Clusters
On September 20, Yang Sheng, Deputy Commissioner of the National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that China will support the scaled-up, intensive, and high-end development of its pharmaceutical industry. The NMPA will encourage pharmaceutical enterprises to build smart factories and green factories. Continued support will be directed to key regions including the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Twin-City Economic Circle, with a specific goal of cultivating three to five biopharmaceutical innovation clusters that are internationally competitive. The NMPA also plans to support expanded opening-up and cooperation, encouraging foreign-invested enterprises to introduce originator drugs and high-end medical equipment for domestic production. Concurrently, it will support Chinese companies in expanding overseas markets, aiming to make Chinese medicines and medical devices available to people worldwide.
Read sourceChina's NMPA Encourages Foreign Investment in Domestic Drug and Medical Device Production
On September 20, Yang Sheng, Deputy Director of China's National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that the agency will support the scaled-up, intensive, and high-end development of the pharmaceutical industry. The NMPA will encourage pharmaceutical enterprises to build smart and green factories. It will continue to support industry development in key regions including the Beijing-Tianjin-Hebei area, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Twin-City Economic Circle, aiming to cultivate three to five internationally competitive biopharmaceutical innovation clusters. The NMPA will also support expanded openness and cooperation in the pharmaceutical sector by encouraging foreign investment to bring originator drugs and high-end medical equipment into domestic production. Additionally, the agency will support Chinese enterprises in expanding overseas to make Chinese medicines and medical devices available globally.
Show 2 older updatesHide older updates
China's NMPA Encourages Foreign Investment for Domestic Production of Originator Drugs and High-End Medical Equipment
On September 20, at a press conference hosted by the State Council Information Office, Yang Sheng, Deputy Commissioner of the National Medical Products Administration (NMPA), announced measures to support the scaled-up, intensive, and high-end development of the pharmaceutical industry. The NMPA will encourage pharmaceutical companies to build smart factories and green factories. Continued support will be provided for industry development in key regions including the Beijing-Tianjin-Hebei area, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Twin-City Economic Circle, with a goal to cultivate three to five internationally competitive biopharmaceutical innovation clusters. The NMPA also plans to support expanded openness and cooperation in the pharmaceutical sector by encouraging foreign investors to introduce originator drugs and high-end medical equipment for domestic production. Additionally, the agency will support Chinese enterprises in going global to benefit people worldwide with Chinese medicines and medical devices.
Read sourceChina's NMPA Encourages Foreign Investment in Domestic Drug and Medical Device Production
On September 20, Yang Sheng, Deputy Commissioner of the National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that China will support the scaled-up, intensive, and high-end development of the pharmaceutical industry. The NMPA will encourage pharmaceutical enterprises to build smart factories and green factories. Continued support will be provided for industry development in key regions including the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Economic Circle, with a goal to cultivate three to five internationally competitive biopharmaceutical innovation clusters. The NMPA also plans to support expanded opening-up and cooperation, encouraging foreign-invested enterprises to bring originator drugs and high-end medical equipment into domestic production. Additionally, the agency will support Chinese companies in expanding overseas to make Chinese medicines and medical devices available globally.
Read source